Charles Fuchs leaves Roche to steer ADC pipeline at Tubulis shortly after $401M Series Cnews2026-01-08T11:30:10+00:00January 8th, 2026|Endpoints News|
Diagonal Therapeutics secures $125M in Series B co-led by Sanofi Venturesnews2026-01-08T11:30:00+00:00January 8th, 2026|Endpoints News|
Former Genentech leaders’ protein degrader startup EpiBiologics nets $107Mnews2026-01-08T11:00:33+00:00January 8th, 2026|Endpoints News|
Lilly to pay $1.2B for Ventyx and its NLRP3 drugsnews2026-01-07T21:29:45+00:00January 7th, 2026|Endpoints News|
Immuneering’s pancreatic cancer pill continues to beat standard care, updated first-line data shownews2026-01-07T21:00:19+00:00January 7th, 2026|Endpoints News|
Lux Capital raises $1.5B for its ninth fundnews2026-01-07T20:28:23+00:00January 7th, 2026|Endpoints News|
FDA in 2025 holds fewest number of adcomms since the pandemicnews2026-01-07T18:28:09+00:00January 7th, 2026|Endpoints News|
Post-Hoc Live Jan. 8: Fewer drugs, more chaos — a year under the new FDAnews2026-01-07T17:00:22+00:00January 7th, 2026|Endpoints News|
BridgeBio shares KRAS data; Hutchmed’s Phase 3 success in Chinanews2026-01-07T15:26:03+00:00January 7th, 2026|Endpoints News|
Poplar Therapeutics gets $50M Series A for immunology ambitionsnews2026-01-07T14:45:13+00:00January 7th, 2026|Endpoints News|
